Table 3:
Hazard ratio of atheromatous cardiovascular events associated with a double increase in baseline serum-free kynurenine level (mg/L).
| Free kynurenine (mg/L) | |
|---|---|
| Atheromatous cardiovascular events | |
| Unadjusted HR [95% CI]—P-value | 1.4 [1.17, 1.69]–0.0002 |
| Adjusted HR a [95% CI]—P-value | 1.15 [0.9, 1.4]–0.2 |
| Adjusted HR b [95% CI]—P-value | 1.15 [0.89, 1.5]–0.2 |
| Adjusted HR c [95% CI]—P-value | 1.08 [0.86, 1.4]–0.5 |
a
Model adjusted for age at baseline, sex, high-sensitivity C-reactive protein, serum albumin, urea, diabetes, dyslipidemia, body mass index, smoking status, baseline estimated glomerular filtration rate, urine albumin- or protein-to-creatinine ratio, systolic blood pressure, prescriptions of antihypertensive drugs, lipid-lowering drugs, and antidiabetic drugs.
b
1 + serum-free tryptophan.
c
1 + serum-free indoxyl sulfate, indole-3-acetic acid and p-cresyl sulfate.